Use Of Genetic Technologies Research Articles

Ethics, Genetic Technologies and Equine Sports: The Prospect of Regulation of a Modified Therapeutic Use Exemption Policy

ABSTRACT This article critically reviews the current availability and selected use of genetic technologies for horses, before undertaking an ethical evaluation of current practice and regulatory positions in comparative relation to debates surrounding genetic testing, pre-implantation genetic testing and gene editing in humans. We argue that genetic testing for hereditary disorders is not only justified but should be encouraged on welfare grounds and that genetic testing for performance traits is ethically permissible based on a restricted imperative to genetically edit horses and horse embryos to reduce genetic predisposition to disease and injury. Given the current state of the science, where the effects of gene editing on health and welfare are currently undetermined, space is created for an analytical distinction between equine gene editing for ‘treatment’ and for ‘enhancement’. Gene editing is only justified for purposes of correcting/preventing disease and injury. Current regulation is challenged by apparently conflicting welfare-based ethical imperatives with respect to welfare-based gene editing. We propose modifications to the blanket bans on gene editing with a case-by-case assessment of applications to permit gene editing, based on best welfare interests underwritten by the aim of facilitating fair sport that adapt WADAs International Standard for Therapeutic Use Exemptions, adding an important reporting element. We reject the use of gene editing to obtain currently prohibited competitive advantages. In order to safeguard the welfare of human and equine athletes, we argue that regulatory institutions should urgently collaborate to develop cross-sport international regulations for the use of gene editing, including obligatory reporting of data about the health and welfare of genetically edited horses.

Potentials and Effectiveness of the Tort of Deceit in Addressing Paternity Fraud Issues

Men are becoming increasingly concerned about misattributed paternity. The increasing use of genetic technologies in clinical research increases the potential for misattributed paternity to be identified. This review seeks to answer the question of whether the Tort of Deceit is effective in addressing issues of paternity fraud. The article assesses how the tort of deceit concepts and principles can be used to resolve misrepresentation cases of paternity fraud and to inform the effectiveness of the tort of deceit in resolving such matters. The article concludes that the tort of deceit can be used to claim settlement as it provided a form of legal solution for the damages suffered as a consequence of paternity fraud. Some of the elements of the tort of deceit include false representation, fact, Knowing or reckless as to whether the statement is false, whether there was reliance upon the representation and existence of damage suffered by the plaintiff. The association between material obligation and the burdens generated by parenthood implies that it is ethically acceptable for a man to establish that he is the legal and biological father of a child before accepting this financial liability. Therefore, the tort of deceit concepts can be used to resolve cases of paternity misrepresentation.

Patient perspectives and experiences with in vitro fertilization and genetic testing options.

Objective:Decision-making and patient experiences with embryo selection during in vitro fertilization often include genetic testing options. The purpose of this study was to gain insight about the experiences and perspectives of women using in vitro fertilization and genetic technologies.Methods:Interviews (n = 37) were conducted among female patients who had undergone in vitro fertilization, underwent expanded carrier screening, and were offered pre-implantation genetic testing for aneuploidy between July 2016 and July 2017. The interviews were transcribed and a content analysis was conducted on the transcripts.Results:Categories that emerged from the data analysis included unexpected outcomes, uncertainty, unanticipated emotional consequences, too much emphasis on the woman’s contributions and questions about embryo viability. Patient experiences with genetic technologies during in vitro fertilization played a significant role within these results.Conclusion:The emotional and psychological impacts of infertility during in vitro fertilization were the primary concerns discussed by participants. Future research is needed to identify ways to help manage unexpected outcomes and continuous uncertainty, including the increasing use of genetic technologies, to not add to the psychological burden of infertility. There is a need to explore more support options or counseling services for patients struggling with infertility during in vitro fertilization treatment.

Research progress on polymerase chain reaction diagnosis technique for joint prosthesis infection

Although the incidence of prosthesis joint infection(PJI) is low, it is one of more serious complications recognized by joint surgery because of the difficulty in diagnosis and treatment, so it is very important to diagnose PJI in time. Currently, clinical diagnostic techniques for PJI are immature, and each technique has certain limitations in terms of sensitivity or specificity of diagnosis. In general, the diagnosis of PJI relies mainly on clinical symptoms, laboratory tests and imaging examinations. The detection of pathogenic microorganisms is the basis of laboratory diagnosis and clinical treatment. The results of microbial susceptibility testing are also the main basis for the clinical application of sensitive antibiotics to treat PJI. However, the current positive rate of PJI pathogen culture is not high. In comparison, polymerase chain reaction(PCR) technology does not depend on the premise that unknown microorganisms can be cultured in vitro, and it is rapid and highly sensitive. Therefore, the use of genetic technology, especially PCR technology to diagnose PJI has become one of the current research hot spots. In order to understand the research and development of PCR diagnostic techniques for joint prosthesis infection in recent years, in this paper, the research progress of genetic technology is reviewed, especially PCR technology in the diagnosis of PJI. Key words: Infection; Polymerase chain reaction; Diagnosis; Replacement

Shifting Ethical Boundaries in Forensic Use of DNA

Abstract In this paper we explore shifts in how the law and ethics allow European law enforcement officers to use forensic genetic technologies. We do so by reviewing three technologies, ‘traditional’ (STR-based) forensic DNA profiling, forensic DNA phenotyping and the searching of genetic genealogy databases. In particular, we discuss changes in how ethical boundaries have been placed around what is seen as an appropriate use of genetic technologies in European criminal justice systems. While the ‘type’ of DNA that law enforcement officers are permitted to analyse offers a useful ethical reference point, for newer forensic genomic technologies, ethical scrutiny, we argue, would also look at the specific purpose or use of the technology.

Attitudes of publics who are unwilling to donate DNA data for research

With the use of genetic technology, researchers have the potential to inform medical diagnoses and treatment in actionable ways. Accurate variant interpretation is a necessary condition for the utility of genetic technology to unfold. This relies on the ability to access large genomic datasets so that comparisons can be made between variants of interest. This can only be successful if DNA and medical data are donated by large numbers of people to ‘research’, including clinical, non-profit and for-profit research initiatives, in order to be accessed by scientists and clinicians worldwide.The objective of the ‘Your DNA, Your Say’ global survey is to explore public attitudes, values and opinions towards willingness to donate and concerns regarding the donation of one's personal data for use by others. Using a representative sample of 8967 English-speaking publics from the UK, the USA, Canada and Australia, we explore the characteristics of people who are unwilling (n = 1426) to donate their DNA and medical information, together with an exploration of their reasons. Understanding this perspective is important for making sense of the interaction between science and society. It also helps to focus engagement initiatives on the issues of concern to some publics.

The use of molecular-biological research methods to detect the falsification of livestock products

The article provides information on the use of molecular research methods to determine the species belonging to the protein of animal and plant origin, the discovery of genetically modified plants to prevent the falsification of products. Actual problem is the identification and implementation of histological researches and methods of PCR control of meat products, which allow differentiating the constituent components of samples, since all meat products, passing the stage of technological processing, and in the finished form mainly preserve their morphological features. The use of genetic technology for analyzing the quality of food products for humans and animal feeds is conditioned by the need for a sensitive, rapid and accurate method to prevent and detect falsifications. The complexity of determining the species composition of the protein is that the heat-treated forages (meat-bone meal, fishmeal, granulated feed, dry and canned feeds for cats and dogs) contains denatured proteins that have completely lost their specificity. Methods, such as immune diffusion in gel, isoelectric focusing, used for the identification of raw meat, in this case are unsuitable. The use of the RID method does not make it possible to determine the specificity of animal proteins already after a heat treatment at 80 °C. for 30 minutes. Meanwhile, using molecular genetic techniques, in particular PCR, one percent of beef can be detected, which was heat treated at 120 °C for 10 minutes after 30 cycles of amplification and 0.1% after 35 cycles. The introduction of screening and confirmatory methods of PCR detection of counterfeit foodstuffs, feeds and feed materials allows for effective and prompt detection of cases of fraud, preventing the entry into the circulation of poor quality products and feed, reducing the productivity and poisoning of animals and, as a consequence, obtaining safe and high-quality livestock products.

How should we deal with misattributed paternity? A survey of lay public attitudes

ABSTRACTBackground: Increasing use of genetic technologies in clinical and research settings increases the potential for misattributed paternity to be identified. Yet existing guidance from the President's Commission for the Study of Ethical Problems in Biomedical and Behavioral Research and the Institute of Medicine (among others) offers contradictory advice. Genetic health professionals are thus likely to vary in their practice when misattributed paternity is identified, and empirical investigation into the disclosure of misattributed paternity is scarce. Given the relevance of this ethical dilemma and its significance to users of genetic services, this study aimed to investigate the attitudes of lay people with regard to the disclosure of misattributed paternity. Methods: An online questionnaire was hosted and advertised through Amazon's Mechanical Turk to 200 United States residents aged 18 years or older. Respondents were asked to rate (via a Likert scale) the ethical permissibility of possible actions a clinician may carry out when misattributed paternity is identified. Data analysis consisted of preliminary descriptive analysis, chi-squared analysis, and Wilcoxon signed-rank tests. Results: There was no clear majority support for many of the options surveyed across different contexts, with only six out of ten scenarios displaying some general consensus. Men were more likely to support scenarios where the father is informed of paternity. Importantly, participants' views varied according to whether the desires of the father were previously expressed, suggesting that perceptions of the permissibility of a clinician's action will depend on the interests of all parties affected. Conclusions: This sample of the general public showed attitudes that were, at least to some degree, at variance with some professional guidelines. We give arguments for why at least some of these attitudes might be justified. We argue that case-specific judgments should be made and outline some of the relevant ethical considerations. While general guidelines ought to be considered, context-specific moral judgments cannot be avoided.

Genetics in the cardiovascular ICU

In Brief There is currently an increase in the use of genetic technologies for risk assessment, diagnosis, treatment, and prevention of inheritable causes of mortality and morbidity.1 Patients and families are relying more and more on their nurse's understanding of genetics to guide their care. This article offers a review of the clinical applications of genetics relevant to the nurse practicing in the cardiovascular ICU. There is currently an increase in the use of genetic technologies for risk assessment, diagnosis, treatment, and prevention of inheritable causes of mortality and morbidity. Patients and families are relying more and more on their nurse's understanding of genetics to guide their care. This article offers a review of the clinical applications of genetics relevant to the nurse practicing in the cardiovascular ICU.

Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.

Immune deficiency disorders are a heterogeneous group of diseases of variable genetic aetiology. While the hallmark of immunodeficiency is susceptibility to infection, it is increasingly clear that autoimmunity is prevalent, suggestive of a more general immune dysregulation in some cases. With the increasing use of genetic technologies, the underlying causes of immune dysregulation are beginning to emerge. Here we provide a review of the heterozygous mutations found in the immune checkpoint protein CTLA-4, identified in cases of common variable immunodeficiency disorders (CVID) with accompanying autoimmunity. Study of these mutations provides insights into the biology of CTLA-4 as well as suggesting approaches for rational treatment of these patients.

Reproductive modification in forest plantations: impacts on biodiversity and society.

1000 I. 1000 II. 1001 III. 1014 IV. 1015 V. 1016 1016 References 1016 SUMMARY: Genetic engineering (GE) can be used to improve forest plantation productivity and tolerance of biotic and abiotic stresses. However, gene flow from GE forest plantations is a large source of ecological, social and legal controversy. The use of genetic technologies to mitigate or prevent gene flow has been discussed widely and should be technically feasible in a variety of plantation taxa. However, potential ecological effects of such modifications, and their social acceptability, are not well understood. Focusing on Eucalyptus, Pinus, Populus and Pseudotsuga - genera that represent diverse modes of pollination and seed dispersal - we conducted in-depth reviews of ecological processes associated with reproductive tissues. We also explored potential impacts of various forms of reproductive modification at stand and landscape levels, and means for mitigating impacts. We found little research on potential reactions by the public and other stakeholders to reproductive modification in forest plantations. However, there is considerable research on related areas that suggest key dimensions of concern and support. We provide detailed suggestions for research to understand the biological and social dimensions of containment technologies, and consider the role of regulatory and market restrictions that obstruct necessary ecological and genetic research.

Using green fluorescent protein sheds light on Lupinus angustifolius L. transgenic shoot development

Narrow-leaf lupin (NLL) is the main legume crop grown in rotation with wheat and other cereals in Western Australia. Efforts to improve NLL germplasm by use of genetic technologies have been hampered by the lack of an efficient genetic transformation method, an issue that is in common with dominant crop legumes globally. Prior research has primarily used the bar gene for phosphinothricin (PPT) resistance. The aim of recent research has been to investigate alternative selection methodologies, in order to determine whether the limitations of low frequency of transgenic shoots, combined with chimerism at T0 could be overcome. Investigation of hygromycin resistance as a selectable marker compared to PPT is reported here. The results suggested that hygromycin resistance was a more suitable selectable marker for NLL transformation than PPT. Surprisingly, from investigation of transformation using the GUS reporter gene, it was also observed that transformation frequency was greater when selection treatment was reduced or delayed, compared to the existing protocols. To further investigate this observation, an eGFP expressing construct was prepared. Observations within the first week after Agrobacterium exposure of lupin explants demonstrated that transformation of NLL explant cells was not a rate-limiting step. Instead, the results indicated that the current selection methodology was killing the cells that were competent to regenerate into transgenic shoots. It was concluded that further research on the development of the treated explants should focus on delayed selection and exposure to Agrobacterium of cells below the apical meristem.

Biology, Ecology, and Evolving Management ofHelicoverpa zea(Lepidoptera: Noctuidae) in Sweet Corn in the United States

The corn earworm, Helicoverpa zea (Boddie), is a polyphagous pest found throughout the United States, where it attacks many field and vegetable crops. Although H. zea has long been a traditional pest of sweet corn, its importance to this crop has increased dramatically over the past two decades. In this review, we summarize information critical for current and future management of H. zea in sweet corn production in the United States. First, we discuss the pest status of H. zea and its life history, including migration, infestation and larval development, diapause, overwintering, and abiotic factors that affect its biology. Next we describe monitoring methods, crop protection decision-making processes, chemical control options, and the use of genetic technologies for control of H. zea Alternative H. zea management options including biological control, cultural controls, host plant resistance, and pheromone disruption are also reviewed. The role of climate change and its effects on H. zea and its ecology are discussed, as well as the recent invasion of its relative, Helicoverpa armigera (Hübner), which is a major pest of corn in other parts of the world. To conclude, we suggest future research opportunities for H. zea and H. armigera management in sweet corn.

The Debate on the Use of Genetic Technology and Production of GM Foods in Ghana: Ethical Perspectives

As has been the case in other parts of the world, recent attempts to pass a bill on the use of genetic technology for food production in Ghana have naturally led to intense debates between those who favour the technology and sceptics. This concept paper points out that both sides of the divide rely on arguments that have been used in other places without sufficiently considering how such arguments relate to the overall political aspirations of Ghana. Using a basic Aristotelian principle of the importance of applying appropriate means for the attainment of an end (phronesis), the paper attempts to contextualize the debate and concludes that gene technology can be used in Ghana, if it is purged of the “genomythology” on which it rests and, if the nation will engage in the search for alternatives.Keywords: phronesis, Ghana, GM Foods, biotechnology, ethics

Whole-Genome Sequencing and Disability in the NICU: Exploring Practical and Ethical Challenges.

Clinical whole-genome sequencing (WGS) promises to deliver faster diagnoses and lead to better management of care in the NICU. However,several disability rights advocates have expressed concern that clinical use of genetic technologies may reinforce and perpetuate stigmatization of and discrimination against disabled persons in medical and social contexts. There is growing need, then, for clinicians and bioethicists to consider how the clinical use of WGS in the newborn period might exacerbate such harms to persons with disabilities. This article explores ways to extend these concerns to clinical WGS in neonatal care. By considering these perspectives during the early phases of expanded use of WGS in the NICU, this article encourages clinicians and bioethicists to continue to reflect on ways to attend to the concerns of disability rights advocates, foster trust and cooperation between the medical and disability communities, and forestall some of the social harms clinical WGS might cause to persons with disabilities and their families.

Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.

It is unknown whether racial differences exist in adjuvant chemotherapy initiation among women with similar oncotype DX (ODX) risk scores. We examined whether adjuvant chemotherapy initiation varied by race. Data come from the Phase III, Carolina Breast Cancer Study, a longitudinal, population-based study of North Carolina women diagnosed with breast cancer between 2008 and 2014. We used modified Poisson regression and report adjusted relative risk (aRR) and 95% confidence intervals (95%CI) to estimate the association between race and adjuvant chemotherapy initiation across ODX risk groups among women who received the test (n = 541). Among women who underwent ODX testing, 54.2, 37.5, and 8.3% of women had tumors classified as low-, intermediate-, and high-risk groups, respectively. We observed no racial variation in adjuvant chemotherapy initiation. Increasing ODX risk score (aRR = 1.39, 95%CI = 1.22, 1.58) and being married (aRR = 2.92, 95%CI = 1.12, 7.60) were independently associated with an increased likelihood of adjuvant chemotherapy in the low-risk group. Among women in the intermediate-risk group, ODX risk score (aRR = 1.15, 95%CI = 1.11, 1.20), younger age (aRR = 1.95, 95%CI = 1.35, 2.81), larger tumor size (aRR = 1.70, 95%CI = 1.22, 2.35), and higher income were independently associated with increased likelihood of adjuvant chemotherapy initiation. No racial differences were found in adjuvant chemotherapy initiation among women receiving ODX testing. As treatment decision-making becomes increasingly targeted with the use of genetic technologies, these results provide evidence that test results may drive treatment in a similar way across racial subgroups.

Genetics and insect pest management in agriculture.

Abstract Genetics has long played a role in the history of insect pest management, and changes in the genetic methods used reflect changes that have occurred in the field itself over time. Beginning from simple collections of mutations and the development of chromosome linkage maps, many of the early applications of genetic technology were focused on the development of new strains for the sterile insect technique as a form of biological control. Since that time, and as the field of genetics underwent a true merger with molecular biology, the focus shifted almost entirely to methods using molecular technology. These methods had the advantage of being more broadly applicable to control of a wide range of pest species, and this did much to move the field away from the frustrations often associated with attempts to transfer genetic tools developed in Drosophila directly to these species. The latest applications of molecular genetic technologies in the area of genetically based control methods now also include cutting-edge systems for genome editing and the use of RNA inhibition for selectively knocking out the expression of individual genes. Finally, as the field of genetics has shifted its focus from the analysis of individual genes to that of entire genomes, new and exciting prospects are opening up for improvements in use of genetic technology for the management of insect pests.

Use of genetic technologies to compare medicines.

In order to ensure that patients receive the safest and most effective medicines possible, it is often necessary to compare medicines and assess the extent to which they are similar in their clinical impact. Full clinical trials with appropriate endpoints remain the only method to compare the clinical impact of two medicines with absolute certainty. Other available methods (including physicochemical analysis, genomics, and transcriptomics) can provide partial information about certain aspects of a medicine's biological impact, with possible clinical implications. Especially for biologics and non-biological complex drugs, which are more difficult to characterize by physicochemical means than small molecules, genomics and transciptomic studies can yield valuable insights for physicians, regulators, and drug developers. In this review, we cite and summarize a variety of studies that exemplify the emerging science of applying genomics and transcriptomics technologies to compare medicines. We discuss key aspects of experimental design, conduct of genetic assays, and advanced data analysis, all of which are critical for the successful execution of such studies. Finally, we propose new areas for which such studies can be applied to maximize patient benefit and reduce safety issues.

Genes are not information: Rendering plant genetic resources untradeable through genetic restoration practices

Genetic commodification relies on methods that treat genes as information. By representing genes as information, scientists produce standardized and stable objects that are easily tradable. In this paper, I argue that a Midwestern plant conservation science institution (MPCSI) challenges genetic commodification through distinct knowledge-making and social practices. In particular, scientists at this institution treat genes not as information, but as contextual and contingent entities. By employing genetic technologies that deemphasize the code metaphor of genes, these scientists make genes unavailable to trade as information.I analyze the socionatural implications of this institution’s use of genetic technology in native ecosystem restoration. Drawing from interviews and participant observation, I focus on specific techniques used by the MPCSI’s scientists to view genes as embodied relational entities, rather than abstract information. I illustrate how these technologies allow the MPCSI to challenge the epistemologies and methodologies that are crucial to producing genetic commodities.Additionally, I illustrate how the MPCSI serves as a model for plant science institutions to reconceptualize their use of banked plant genetic resources. This model complicates the commodity speculation paradigm common to bioprospectors. At the same time, this genetic restoration approach relies on and produces different engagements with markets. I detail the MPCSI’s emerging relationship with commercial seed nurseries to illustrate how decommodification is integral to commodification. Finally, I argue that although the MPCSI’s genetic restoration strategy necessitates limited market engagements, their scientific practices and institutional relationships produce drastically different socioecological outcomes compared to institutions that treat genes as information.

The concept of human dignity in the ethics of genetic research.

Despite criticism that dignity is a vague and slippery concept, a number of international guidelines on bioethics have cautioned against research that is contrary to human dignity, with reference specifically to genetic technology. What is the connection between genetic research and human dignity? In this article, I investigate the concept of human dignity in its various historical forms, and examine its status as a moral concept. Unlike Kant's ideal concept of human dignity, the empirical or relational concept takes human dignity as something that is affected by one's circumstances and what others do. I argue that the dignity objection to some forms of genetic research rests on a view of human nature that gives humans a special status in nature - one that is threatened by the potential of genetic research to reduce individuals to their genetic endowment. I distinguish two main philosophical accounts of human nature. One of these, the Aristotelian view, is compatible with the use of genetic technology to help humans realize their inherent potential to a fuller extent.